| Literature DB >> 29967729 |
Loretta Giummarra1, Sheila G Crewther1, Nina Riddell1, Melanie J Murphy1, David P Crewther2.
Abstract
PURPOSE: RNA sequencing analysis has demonstrated bidirectional changes in metabolism, structural and immune pathways during early induction of defocus induced myopia. Thus, the aim of this study was to investigate whether similar gene pathways are also related to the more excessive axial growth, ultrastructural and elemental microanalytic changes seen during the induction and recovery from form-deprivation myopia (FDM) in chicks and predicted by the RIDE model of myopia.Entities:
Keywords: Bile acid metabolism; Gene set enrichment analysis; Mitochondrial energy metabolism; Myopia; Neurotransmission
Year: 2018 PMID: 29967729 PMCID: PMC6026464 DOI: 10.7717/peerj.5048
Source DB: PubMed Journal: PeerJ ISSN: 2167-8359 Impact factor: 2.984
Figure 1MRI images of chick eye following 10 days of FDM induction and 3 days recovery.
(A) Monocular form-deprivation of the right eye (RE) for 10 days demonstrates abnormal ocular growth, excess vitreal volume, and thinned choroid of RE compared to its fellow left eye (LE). (B) 72 h post-occlusion recovery (i.e., 72 h normal visual experience) resulted in vitreous volume decrease and choroidal expansion. Previous studies (Liang et al., 2004) have shown ∼300% increase in choroidal thickness in RE compared to LE after three days recovery from FD. Note: Images (same magnification) in (B) slightly more dorsal than in (A). Image credit: G Egan.
Figure 2Ocular Biometrics for FDMI and FDMR.
Mean (±SE) measures of refractive status, axial length (AL) and vitreous chamber depth (VCD). To complement the data reported by McGlinn et al. (2007), (A) refraction and (B) AL & VCD were collected during 6 h and 72 h of normal development and 6 h and 72 h following seven-days induction of myopia. Refraction, AL & VCD measures for 24 h recovery after prolonged (i.e., 10 days) form deprivation is shown in (C) and (D). Both refractive state and axial length changes were highly correlated (r = .78) during occluder wear (E). Note: Measures for anterior chamber and lens thickness are included in Fig. S1.
Pathways enriched between 6 h and 72 h of FD induction.
Mean Normalised Enrichment Score (NES) and false discovery rate (FDR) for the biological pathways identified by GSEA in FD induction. Most genes responding to FD are involved in mitochondrial energy metabolism. The NES reflects the degree to which a set of genes is over-represented at either the top or bottom of a ranked list of genes while also taking into account differences in pathway size (i.e. gene-set size) and is the primary statistic for examining enrichment results, and for comparing results across pathways.
| Pathway | Core genes | Database | NES | FDR |
|---|---|---|---|---|
| Huntingtons disease | APAF1, ATP5C1, ATP5D, ATP5E, ATP5F1, ATP5H, ATP5O, BDNF, CASP3, CASP8, CLTA, COX4I1, COX5A, COX6A1, COX6C, COX7A2, COX7A2L, COX7C, COX8A, CYCS, DNAH3, DNAI1, DNAL1, DNALI1, GPX1, HDAC2, IFT57, NDUFA1, NDUFA10, NDUFA2, NDUFA4, NDUFA5, NDUFA6, NDUFA7, NDUFA8, NDUFB1, NDUFB10, NDUFB3, NDUFB4, NDUFB5, NDUFB6, NDUFB8, NDUFB9, NDUFC1, NDUFC2, NDUFS1, NDUFS3, NDUFS4, NDUFS6, NDUFS7, NDUFS8, NDUFV3, PLCB1, PLCB4, POLR2D, POLR2F, POLR2J, POLR2L, PPID, SDHA, SLC25A4, SLC25A6, SOD2, TAF4, TBP, TBPL1, TFAM, UQCR10, UQCR11, UQCRFS1, UQCRH, VDAC3 | KEGG | 1.76 | 0.15 |
| Oxidative phosphorylation | ATP5C1, ATP5D, ATP5E, ATP5F1, ATP5H, ATP5I, ATP5J2, ATP5O, ATP6V0D2, ATP6V1G1, COX11, COX15, COX17, COX4I1, COX5A, COX6A1, COX6C, COX7A2, COX7A2L, COX7C, COX8A, NDUFA1, NDUFA10, NDUFA2, NDUFA4, NDUFA5, NDUFA6, NDUFA7, NDUFA8, NDUFB1, NDUFB10, NDUFB3, NDUFB4, NDUFB5, NDUFB6, NDUFB8, NDUFB9, NDUFC1, NDUFC2, NDUFS1, NDUFS3, NDUFS4, NDUFS6, NDUFS7, NDUFS8, NDUFV3, PPA1, PPA2, SDHA, UQCR10, UQCR11, UQCRFS1, UQCRH | KEGG | 1.81 | 0.16 |
| Mitochondrial protein import | BCS1L, CHCHD4, COX17, DNAJC19, GRPEL1, HSCB, HSPD1, PAM16, PMPCA, PMPCB, SAMM50, SLC25A12, SLC25A4, SLC25A6, TIMM13, TIMM17A, TIMM22, TIMM44, TIMM9, TOMM22, TOMM5, TOMM7 | Reactome | 1.80 | 0.16 |
| One carbon pool by folate | ATIC, DHFR, GART, MTFMT, MTHFD1, MTHFD1L, MTHFS, TYMS | KEGG | 1.74 | 0.17 |
| Cholesterol biosynthesis | DHCR7, FDFT1, GGPS1, HMGCR, HMGCS1, IDI1, MSMO1, NSDHL, SQLE | Reactome | 1.77 | 0.17 |
| Antigen processing cross presentation | CD36, CTSS, NCF4, PSMA1, PSMA2, PSMA3, PSMA5, PSMA6, PSMA7, PSMB1, PSMB2, PSMB3, PSMC1, PSMC2, PSMC3, PSMC5, PSMD1, PSMD10, PSMD3, PSMD5, RPS27A, SEC61B, SEC61G, TAP1, UBA52 | Reactome | 1.74 | 0.18 |
| Alzheimers disease | NDUFB6, CYCS, NDUFB3, NDUFA8, UQCR11, NDUFC2, ATP5F1, ATP5E, NDUFB5, UQCR10, COX4I1, COX6A1, COX7C, NDUFB10, NDUFB1, CASP8, NDUFV3, NDUFA6, ATP5H, COX7A2, RYR3, NDUFA2, NDUFC1, NDUFS1, NDUFA1, SDHA, NDUFB8, NDUFA4, NDUFA5, APAF1, UQCRH, ATP5O, NDUFA7, NDUFS6, NDUFS4, ATP5D, ATP5C1, NDUFB9, CACNA1D, NDUFS8, NDUFS3, NDUFS7, CASP3, COX8A, COX6C, COX5A, NDUFA10, ATP2A1, COX7A2L, TNFRSF1A, UQCRFS1, PSEN1, NDUFB4, IL1B, PLCB1, NCSTN, PLCB4 | KEGG | 1.74 | 0.19 |
| Parkinsons disease | APAF1, ATP5C1, ATP5D, ATP5E, ATP5F1, ATP5H, ATP5O, CASP3, COX4I1, COX5A, COX6A1, COX6C, COX7A2, COX7A2L, COX7C, COX8A, CYCS, GPR37, NDUFA1, NDUFA10, NDUFA2, NDUFA4, NDUFA5, NDUFA6, NDUFA7, NDUFA8, NDUFB1, NDUFB10, NDUFB3, NDUFB5, NDUFB6, NDUFB8, NDUFB9, NDUFC1, NDUFC2, NDUFS1, NDUFS3, NDUFS4, NDUFS6, NDUFS7, NDUFS8, NDUFV3, PARK7, PPID, SDHA, SLC25A4, SNCAIP, UBE2L3, UQCR10, UQCR11, UQCRH, VDAC3 | KEGG | 1.77 | 0.19 |
| TCA cycle and respiratory electron transport | ATP5C1, ATP5D, ATP5E, ATP5F1, ATP5H, ATP5I, ATP5J2, ATP5O, COX4I1, COX5A, COX6A1, COX6C, COX7A2L, COX7C, COX8A, CYCS, D2HGDH, DLD, IDH3A, LDHB, NDUFA1, NDUFA10, NDUFA2, NDUFA4, NDUFA5, NDUFA6, NDUFA7, NDUFA8, NDUFB1, NDUFB10, NDUFB3, NDUFB5, NDUFB6, NDUFB8, NDUFB9, NDUFC1, NDUFC2, NDUFS1, NDUFS3, NDUFS4, NDUFS6, NDUFS7, NDUFS8, NDUFV3, NNT, SDHA, SUCLG1, SUCLG2, UQCR11, UQCRH | Reactome | 1.72 | 0.19 |
| Respiratory electron transport | COX4I1, COX5A, COX6A1, COX6C, COX7A2L, COX7C, COX8A, CYCS, NDUFA1, NDUFA10, NDUFA12, NDUFA2, NDUFA4, NDUFA5, NDUFA6, NDUFA7, NDUFA8, NDUFB1, NDUFB10, NDUFB3, NDUFB4, NDUFB5, NDUFB6, NDUFB8, NDUFB9, NDUFC1, NDUFC2, NDUFS1, NDUFS3, NDUFS4, NDUFS6, NDUFS7, NDUFS8, NDUFV3, SDHA, UQCR11, UQCRFS1, UQCRH | Reactome | 1.81 | 0.21 |
| Respiratory electron transport ATP synthesis by chemiosmotic coupling and heat production by uncoupling proteins | ATP5C1, ATP5D, ATP5E, ATP5F1, ATP5H, ATP5I, ATP5J2, ATP5O, COX4I1, COX5A, COX6A1, COX6C, COX7A2L, COX7C, COX8A, CYCS, NDUFA1, NDUFA10, NDUFA12, NDUFA2, NDUFA4, NDUFA5, NDUFA6, NDUFA7, NDUFA8, NDUFB1, NDUFB10, NDUFB3, NDUFB4, NDUFB5, NDUFB6, NDUFB8, NDUFB9, NDUFC1, NDUFC2, NDUFS1, NDUFS3, NDUFS4, NDUFS6, NDUFS7, NDUFS8, NDUFV3, SDHA, UCP3, UQCR11, UQCRFS1, UQCRH | Reactome | 1.83 | 0.23 |
| Translation | EEF1B2, EIF2B1, EIF2B2, EIF2S1, EIF2S2, EIF2S3, EIF3D, EIF3H, EIF3I, EIF3J, EIF4EBP1, EIF4H, EIF5B, RPL10A, RPL11, RPL13, RPL14, RPL18A, RPL19, RPL21, RPL22, RPL23A, RPL24, RPL26L1, RPL27, RPL27A, RPL29, RPL30, RPL32, RPL35, RPL35A, RPL36, RPL36A, RPL37, RPL37A, RPL38, RPL39, RPL5, RPL6, RPL7, RPL8, RPLP1, RPLP2, RPN1, RPS10, RPS11, RPS14, RPS15, RPS15A, RPS16, RPS2, RPS20, RPS23, RPS24, RPS25, RPS26, RPS27A, RPS28, RPS29, RPS3, RPS3A, RPS4X, RPS6, RPS7, RPS8, RPSA, SEC61B, SEC61G, SPCS1, SPCS2, SPCS3, SRP19, SRP72, SSR3, UBA52 | Reactome | 1.69 | 0.24 |
| ER phagosome pathway | PSMA1, PSMA2, PSMA3, PSMA5, PSMA6, PSMA7, PSMB1, PSMB2, PSMB3, PSMC1, PSMC2, PSMC3, PSMC5, PSMD1, PSMD10, PSMD3, PSMD5, RPS27A, SEC61B, SEC61G, TAP1, UBA52 | Reactome | 1.67 | 0.25 |
Summary statistics for clusters of pathways enriched during FDMI and normal development.
Mean Normalised Enrichment Score (NES), false discovery rate (FDR) and signal strength statistic (Signal) for the biological pathways implicated by GSEA in control and FDM. Normal eye development implicated 10 cluster of pathways showing average signal strength while form-deprivation induction implicated 18 clusters of pathways. Pathways shown here only include clustered pathways as represented in Figs. 3 and 4 and do not include pathways that were unclustered. Further detail on the unclustered pathways can be found in File 1. The NES reflects the degree to which a set of genes is overrepresented at either the top or bottom of a ranked list of genes while also taking into account differences in pathway size (i.e., geneset size). NES is the primary statistic for examining enrichment results, and for comparing results across pathways. The percentage signal strength statistic reflects the proportion of the core set of genes that contribute most to a given pathway’s enrichment by accounting for particular genes position in the ranked list. A high signal strength indicates that the genes within a pathway are located close to the top (positive NES) or bottom (negative NES) of the ranked gene list. If the core genes are spread throughout the ranked list, then the signal strength decreases towards zero (Mootha et al., 2003; Subramanian et al., 2005).
| Cluster | Control | FDMI | ||||||
|---|---|---|---|---|---|---|---|---|
| Pathways in cluster | NES | FDR | Signal | Pathways in cluster | NES | FDR | Signal | |
| Cell cycle, mitotic | 5 | −2.233 | 0.019 | 31% | 3 | −2.253 | 0.009 | 98% |
| Cell maintenance & survival | – | – | – | – | 28 | −2.180 | 0.014 | 117% |
| Clatherin-mediated endocytosis (CME) | – | – | – | – | 2 | −2.014 | 0.032 | 81% |
| Complement and coagulation cascades (CCC) | – | – | – | – | 2 | 2.708 | 0.003 | 140% |
| Cytochrome p450 | 2 | 2.247 | 0.025 | 47% | 5 | 2.629 | 0.002 | 133% |
| Cytokine pathways | 2 | 2.717 | 0.002 | 40% | – | – | – | – |
| Neuron structure/growth | – | – | – | – | 5 | −2.321 | 0.007 | 80% |
| Fatty acid (FA) metabolism | – | – | – | – | 2 | −1.886 | 0.032 | 84% |
| Glucosaminoglycan (GAG) metabolism | 4 | 2.121 | 0.029 | 40% | – | – | – | – |
| Ion channel transport | – | – | – | – | 2 | −2.331 | 0.007 | 99% |
| Mitochondrial energy metabolism | – | – | – | – | 7 | 2.396 | 0.005 | 47% |
| Neurotransmission | 5 | −2.522 | 0.011 | 37% | 8 | −2.423 | 0.007 | 103% |
| Peroxisome | 2 | −2.221 | 0.017 | 40% | – | – | – | – |
| Phospholipid metabolism | 2 | −2.134 | 0.026 | 28% | 3 | −1.939 | 0.027 | 57% |
| Signal transduction, growth factors (GF) | – | – | – | – | 4 | −1.984 | 0.021 | 66% |
| Signal transduction, g-protein coupled receptors (GPCR) | 7 | 2.572 | 0.019 | 52% | 7 | 2.683 | 0.010 | 122% |
| Signal transduction, mitogen-activated protein kinases (MAPK) | – | – | – | – | 4 | −1.931 | 0.028 | 67% |
| Signal transduction, nerve growth factor (NGF) | – | – | – | – | 5 | −2.195 | 0.014 | 84% |
| Transcription | – | – | – | – | 10 | −2.218 | 0.013 | 120% |
| Translation | – | – | – | – | 8 | 2.731 | 0.001 | 46% |
| Ubiquitin-mediated proteolysis | 3 | −2.491 | 0.006 | 39% | – | – | – | – |
| Vesicle-mediated transport | 3 | −2.152 | 0.025 | 40% | 3 | −2.097 | 0.013 | 103% |
Figure 3Enrichment map for highly clustered pathways in normal eye development.
Gene set enrichment analysis revealed 61 biological pathways that can be functionally grouped into 10 clusters using a co-efficient of similarity altered during the 10 days of normal eye development in retina/RPE/choroid. Note: Each node represents a biological pathway from File S1. The colour of each node emphasises the direction of expression and normalised enrichment score (NES). Node size is relative to the number of genes in the pathway. Thickness of the connections (green) between each node reflects the degree of similarity between each gene set. Twenty-six pathways did not meet the clustering similarity coefficient of 0.5 and hence are not shown here. Note cluster names: GAG, glycosaminoglycan; GPCR, g-protein coupled receptors.
Figure 4Enrichment map for highly clustered pathways in form deprivation induction and recovery.
Axial elongation during 10 days of form-deprivation compared to normal unoccluded controls resulted in 130 altered pathways in retina/RPE choroid (inner node) while 24 h recovery (outer annulus) identified only one statistically significant pathway i.e., bile acid & bile salt metabolism. Pathways not statistically enriched during FDMR are shown for comparison purposes. Notably, expression profiles of FDMI and FDMR are consistent despite the fact that only the FDMR data includes choroidal tissue. Pathways highly expressed during induction (red inner node) were often suppressed during normal vision and recovery (blue outer annulus) and vice versa. Note: Each node represents a biological pathway from File S1. The colour of each node emphasises the direction of expression and normalised enrichment score (NES). Node size is relative to the number of genes in the pathway. Thickness of the connections (green) between each node reflects the degree of similarity between each gene set. There were 22 unclustered pathways in FDMI that did not meet the clustering similarity coefficient of 0.5. Note cluster names: CCC, complement and coagulation cascades; CME, clatherin-mediated endocytosis; FA, Fatty acid; GF, growth factors; GPCR, g-protein coupled receptors; MAPK, mitogen-activated protein kinases; NGF, nerve growth factor.
Figure 5Median expression of pathways involved in mitochondrial metabolism.
Graphs of the seven mitochondrial metabolism pathways with significant expression shifts across 240 h of occluder wear relative to unoccluded controls (A) Alzheimer’s disease, (B) Huntington’s disease, (C) Parkinson’s disease, (D) Oxidative phosphorylation, (E) Respiratory electron transport, (F) Respiratory electron transport/ATP synthesis by chemiosmotic coupling and heat production by uncoupling proteins, (G) TCA cycle and respiratory electron transport.
Figure 6Median expression of pathways involved in neurotransmission during normal ocular development and in FDMI.
Graphs of the neurotransmission-related pathways with significant expression shifts during normal ocular development (dotted lines) and FDMI (solid lines) are shown. (A–D) Four pathways were significant in both normal development and FDMI. The leading-edge subsets for these pathways identified 115 common core genes shared within these pathways during normal development and during FDMI and 27 other core genes specific to normal development and nine specific to FDMI (File S1). (E–H) Graphs indicate FDMI induced down regulation of expression shift in four additional neurotransmission-related pathways with significant expression shifts during FDMI (solid lines) only. These pathways were not significant during normal ocular development but data are shown for comparison purposes (dotted lines). (A) Neuronal system (B) Neurotransmitter release cycle (C) Neurotransmitter receptor binding & downstream transmission in the postsynaptic cell (D) Transmission across chemical synapse (E) Activation of NMDA receptor upon glutamate binding and postsynaptic events (F) CREB phosphorylation through the activation of RAS (G) Long-term potentiation (H) Post-NMDA receptor activation events.
Figure 7Median expression of pathways involved in ion transport during normal ocular development and in FDMI.
Expression of the (A) Ion channel transport and (B) Ligand-gated ion channel transport pathways with significant expression shifts during FDMI (solid lines) compared to normal development (dotted lines) are shown. The ‘Ligand-gated ion channel transport pathway’ pathway was also significantly altered during normal development and was clustered with the neurotransmission pathway.
Figure 8Median expression of pathways involved in the complement and coagulation cascade.
Graphs indicate greater expression shift in the complement & coagulation cascade between 72 h and 240 h of occluder wear for both (A) formation of fibrin clot/clotting cascade and (B) complement and coagulation cascades. Note that the ‘complement and coagulation cascades’ pathway was also significantly altered during normal development.
Figure 9Median expression of pathways involved in cytochrome p450 metabolism.
Graph indicates enhanced expression in cytochrome p450 related pathways in FDMI compared to normal development. (A) Biological oxidations (B) Cytochrome P450 arranged by substrate type (C) Drug metabolism, cytochrome P450 (D) Drug metabolism of xenobiotics by cytochrome P450 (E) Phase 1 functionalization of compounds.
Figure 10Median expression of core genes in the bile acid and bile salt metabolism pathway during FDM.
Graphs shows median change of the core genes during normal ocular development, FDMI, and FDMR. This pathway was found to be significant for FDMI (left, solid line) and FDMR (right, solid line) but not in normal development. Note: Median expression value was calculated based on core genes identified in each experimental group. This pathway was not significantly altered during normal ocular development but data are shown for comparison purposes (dotted line).